EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Targeting CD20 in Primary Membranous Nephropathy Serologically and Histologically Negative for PLA2R: Is Obinutuzumab Superior to Rituximab?

Huiling Cao, Yumei Feng, Xueting Li, Ben Ke iD, Limin Gong

Drug Design, Development and Therapy · 2025-11 · Volume 19 · 9983-9992

DOI: 10.2147/dddt.s560746 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-11. Verfasst von Huiling Cao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Rituximab, Receptors, Phospholipase A2, Antigens, CD20. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousRituximabReceptors, Phospholipase A2Antigens, CD20Antibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAged

Stichwörter der Autor:innen

M-type phospholipase A2 receptoranti-CD20 monoclonal antibodyobinutuzumabprimary membranous nephropathyrituximab

Substanzen

RituximabReceptors, Phospholipase A2obinutuzumabAntigens, CD20Antibodies, Monoclonal, HumanizedPLA2R1 protein, human

Autor:innen und Institutionen

  • Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.
  • Department of Emergency, Pingxiang People's Hospital, Pingxiang, Jiangxi, 337055, People's Republic of China.
  • Department of General Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.

ORCID-Profile: Ben Ke

Zitieren

APA

Cao, H., Feng, Y., Li, X., Ke, B., & Gong, L. (2025). Targeting CD20 in Primary Membranous Nephropathy Serologically and Histologically Negative for PLA2R: Is Obinutuzumab Superior to Rituximab?. Drug Design, Development and Therapy, Volume 19, 9983-9992. https://doi.org/10.2147/dddt.s560746

Vancouver

Cao H, Feng Y, Li X, Ke B, Gong L. Targeting CD20 in Primary Membranous Nephropathy Serologically and Histologically Negative for PLA2R: Is Obinutuzumab Superior to Rituximab?. Drug Design, Development and Therapy. 2025;Volume 19:9983-9992. doi:10.2147/dddt.s560746

BibTeX
@article{Cao2025,
  author = {Cao, Huiling and Feng, Yumei and Li, Xueting and Ke, Ben and Gong, Limin},
  title = {Targeting CD20 in Primary Membranous Nephropathy Serologically and Histologically Negative for PLA2R: Is Obinutuzumab Superior to Rituximab?},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  volume = {Volume 19},
  pages = {9983--9992},
  doi = {10.2147/dddt.s560746}
}
Kostenlos starten →